ClinicalTrials.gg
CompletedNCT00745290TKAUpdated Aug 6, 2013Results posted

A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty

A Phase 3 interventional study of Bupivacaine HCl and SKY0402 in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
20th of 364
245 · median 70
Started
2008
with 8 others
Phase 3
42 of 364
2 open now
Registered
13th of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 20th largest by enrollment, is one of 9 that started in 2008, is one of 42 in phase 3, and was the 13th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective is to demonstrate that SKY0402 is superior when compared to bupivacaine HCl in the management of postoperative pain for patients undergoing total knee arthroplasty.

Read the detailed description

The primary objective is to demonstrate the superiority of SKY0402, compared with bupivacaine HC1, with respect to the extent and duration of the analgesic effect achieved by a single intraoperative administration of the study drug via local infiltration in subjects undergoing total knee arthroplasty (TKA).

The secondary objectives are to evaluate additional efficacy parameters and characterize the safety profile of SKY0402 in comparison with bupivacaine HCl.

03

Conditions studied

  • Postoperative Pain

Keywords

  • Total knee arthroplasty
  • Pain
  • Analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ≥18 years of age at the Screening Visit.
  2. Female subjects only: , surgically sterile, or willing to use acceptable means of for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
  3. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
  4. American Society of Anesthesiology (ASA) Physical Classification System class 1-4.
  5. Able and willing to comply with all study visits and procedures.
  6. Able to speak, read, and understand the language of the form, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
  7. Willing and capable of providing written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
  2. Use of any of the following medications within the times specified before surgery:

    • Long-acting opioid medication within 3 days.
    • Any opioid medication within 24 hours.
  3. Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site being administered study drug (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.), which have the potential to confound the postoperative study assessments.
  4. Body weight less than 60 kilograms (\~132 pounds).
  5. to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
  6. Contraindication to epinephrine, such as concurrent administration of ergot-type drugs, monoamine oxidase (MAO) inhibitors or antidepressants of triptoline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  7. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  8. Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  9. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
  10. Current or historical evidence of any disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
  11. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an status, such as blood dyscrasias, /AIDS, or recent chemotherapy.

    In addition, the subject will be ineligible to receive study drug if he or she meets the following criterion during surgery:

  12. Any clinically significant event or condition uncovered during surgery (e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject's postoperative course.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Active comparator
    Bupivacaine HCl

    Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration

    Drug: Bupivacaine HCl

  • Other
    SKY0402

    Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration

    Drug: SKY0402

Interventions

  • 200 mg bupivacaine HCl

    Also known as: Marcaine

  • 600 mg SKY0402 (study drug).

    Also known as: DepoBupivacaine

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores

    The subject's pain intensity was assessed with activity (NRS-A), while actively flexing the involved knee from the maximum extension point to the maximum flexion point possible. The subject responded to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"

    Time frame: through 72 hours post surgery

Secondary outcomes

  1. Number of Participants With Adverse Events Through 96 Hours and Serious Adverse Events Through 30 Days

    Time frame: through 30 days

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine HClSKY0402
Started123122
Completed123122
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores

The subject's pain intensity was assessed with activity (NRS-A), while actively flexing the involved knee from the maximum extension point to the maximum flexion point possible. The subject responded to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"

Time frame:
through 72 hours post surgery
Reported as:
Mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores
Units on a scale*hoursBupivacaine HClSKY0402
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores335 ± 113359 ± 124
SecondaryNumber of Participants With Adverse Events Through 96 Hours and Serious Adverse Events Through 30 Days
Time frame:
through 30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine HCl—18/123 (14.6%)107/123 (87%)
SKY0402—12/122 (9.8%)108/122 (88.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventBupivacaine HClSKY0402
CellulitisInfections and infestations0/1233/122
ArthrofibrosisMusculoskeletal and connective tissue disorders3/1230/122
Cardiac failure congestiveCardiac disorders0/1232/122
Atrial fibrillationCardiac disorders2/1230/122
HypoglycemiaMetabolism and nutrition disorders2/1230/122
Deep vein thrombosisVascular disorders2/1230/122
Postoperative wound infectionInfections and infestations1/1231/122
Myocardial InfarctionCardiac disorders0/1231/122
Embolic strokeNervous system disorders0/1231/122
SedationNervous system disorders0/1231/122
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBupivacaine HClSKY0402
NauseaGastrointestinal disorders71/12376/122
ConstipationGastrointestinal disorders47/12356/122
VomitingGastrointestinal disorders42/12338/122
AnemiaBlood and lymphatic system disorders28/12328/122
PyrexiaGeneral disorders16/12314/122
PruritisSkin and subcutaneous tissue disorders16/12311/122
Anemia postoperativeInjury, poisoning and procedural complications10/12312/122
Procedural painInjury, poisoning and procedural complications9/12310/122
Oedema peripheralGeneral disorders5/1239/122
InsomniaPsychiatric disorders9/1239/122

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bupivacaine HClSKY0402Total
<=18 years000
Between 18 and 65 years6752119
>=65 years5670126
Age Continuous
Age Continuous(years)Bupivacaine HClSKY0402Total
Mean64.8 ± 10.466.8 ± 10.665.8 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine HClSKY0402Total
Female7383156
Male503989
Region of Enrollment
Region of Enrollment(participants)Bupivacaine HClSKY0402Total
United States123122245
08

Study locations

19 sites
  • West Alabama Research, Inc.
    Birmingham, Alabama 35209, United States
  • Horizon Research Group, Inc., Alabama Orthopaedic Clinic
    Mobile, Alabama 36608, United States
  • Drug Research and Analysis Corporation
    Montgomery, Alabama 36106, United States
  • Sun Health Research Institute, Core Institute
    Sun City West, Arizona 85375, United States
  • Scripps
    La Jolla, California 92037, United States
  • Accurate Clinical Trials, Inc.
    Laguna Hills, California 92653, United States
  • Physicans Clinical Research Corp.
    Laguna Hills, California 92653, United States
  • Cedars of Sinai Medical Center
    Los Angeles, California 90048, United States
  • Atlanta Knee and Sports Medicine
    Decatur, Georgia 30033, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Insall Scott Kelly Institute
    New York, New York 10065, United States
  • CTMG, Inc.
    Greenville, North Carolina 27834, United States
  • Duke University Medical Center
    Raleigh-Durham, North Carolina 27710, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Allegheny Pain Management
    Altoona, Pennsylvania 16602, United States
  • Ilumina Clinical Associates
    Johnstown, Pennsylvania 15904, United States
  • Research Associates of Jackson
    Jackson, Tennessee 38301, United States
  • Texas Orthopedic Specialists, PA
    Grapevine, Texas 76051, United States
  • Memorial Hermann City Hospital
    Houston, Texas 77024, United States
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 4 years 7 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2008
First posted
Sep 3, 2008
Start
Aug 2008
Primary completionActual
Jan 2009
CompletionActual
Feb 2009
Results delay requested
Aug 25, 2010
Results first posted
Aug 6, 2013
Last update
Aug 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00745290
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
Aug 2008
Primary completion
Jan 2009
Completion
Feb 2009
Results posted
Aug 6, 2013
Last update
Aug 6, 2013

Study contacts

Joyce Davis, RN
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion